Literature DB >> 8289379

Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.

K Nagy1, M Young, C Baboonian, J Merson, P Whittle, S Oroszlan.   

Abstract

The antiviral activities of two substrate-based inhibitors of human immunodeficiency virus type 1 (HIV-1) protease, UK-88,947 and Ro 31-8959, were studied in acute infections. H9 and HeLaCD4-LTR/beta-gal cells were infected either with HIV-1IIIB or a replication-defective virus, HIV-gpt(HXB-2). Both inhibitors were capable of blocking early steps of HIV-1 replication if added to cells prior to infection. Partial inhibition was also obtained by addition of inhibitor at the time of or as late as 15 min after infection. The inhibitors were ineffective if added 30 min postinfection. The inhibitory effects were studied by cDNA analysis with PCR followed by Southern blot hybridization and by infectivity assays allowing quantitation of HIV-1 in a single cycle of replication. When UK-88,947-treated H9 cells were coinfected with HIV-1 and human T-cell leukemia virus type I only the replication of HIV-1 was inhibited, demonstrating viral specificity. Pretreating the infectious virus stocks with the inhibitors also prevented replication, indicating that the inhibitors block the action of the viral protease and not a cellular protease. A panel of primer sets was used to analyze cDNA from cell lysates by PCR amplification at 4 and 18 h postinfection. Four hours after infection, viral specific cDNA was detected with all of the four primer pairs used: R/U5, nef/U3, 5' gag, and long terminal repeat (LTR)/gag. However, after 18 h, only the R/U5 and nef/U3 primer pairs and not the 5' gag or LTR/gag primer pair were able to allow amplification of cDNA. The results suggest a crucial role of HIV-1 protease in the early phase of viral replication. Although it is not clear what early steps are affected by the protease, it is likely that the target is the NC protein, as referred from our previous reports of the in situ cleavage of the nucleocapsid (NC) protein by the viral protease inside lentiviral capsids. The results suggest that it is not the inhibition of initiation and progression of reverse transcription but the stability of full-size unintegrated cDNA which is affected in the presence of protease inhibitors. Alternatively, the cleavage of the NC protein may be required for the proper formation of preintegration complex and/or for its transport to the nucleus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8289379      PMCID: PMC236512          DOI: 10.1128/JVI.68.2.757-765.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Infection of peripheral blood mononuclear cells and cell lines by cell-free human T-cell lymphoma/leukemia virus type I.

Authors:  N Fan; J Gavalchin; B Paul; K H Wells; M J Lane; B J Poiesz
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

2.  Interactions between HIV-1 nucleocapsid protein and viral DNA may have important functions in the viral life cycle.

Authors:  M Lapadat-Tapolsky; H De Rocquigny; D Van Gent; B Roques; R Plasterk; J L Darlix
Journal:  Nucleic Acids Res       Date:  1993-02-25       Impact factor: 16.971

3.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Authors:  A H Kaplan; J A Zack; M Knigge; D A Paul; D J Kempf; D W Norbeck; R Swanstrom
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

Review 4.  Structure-based inhibitors of HIV-1 protease.

Authors:  A Wlodawer; J W Erickson
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

5.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells.

Authors:  I Miyoshi; I Kubonishi; S Yoshimoto; T Akagi; Y Ohtsuki; Y Shiraishi; K Nagata; Y Hinuma
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

6.  Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection.

Authors:  M I Bukrinsky; N Sharova; T L McDonald; T Pushkarskaya; W G Tarpley; M Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

7.  Studies on the substrate specificity of the proteinase of equine infectious anemia virus using oligopeptide substrates.

Authors:  J Tözsér; D Friedman; I T Weber; I Bláha; S Oroszlan
Journal:  Biochemistry       Date:  1993-04-06       Impact factor: 3.162

8.  Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein.

Authors:  T Dorfman; J Luban; S P Goff; W A Haseltine; H G Göttlinger
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

9.  Productive infection and cell-free transmission of human T-cell leukemia virus in a nonlymphoid cell line.

Authors:  P Clapham; K Nagy; R Cheingsong-Popov; M Exley; R A Weiss
Journal:  Science       Date:  1983-12-09       Impact factor: 47.728

10.  The two zinc fingers in the human immunodeficiency virus type 1 nucleocapsid protein are not functionally equivalent.

Authors:  R J Gorelick; D J Chabot; A Rein; L E Henderson; L O Arthur
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more
  18 in total

1.  New Approach for Inhibition of HIV Entry: Modifying CD4 Binding Sites by Thiolated Pyrimidine Derivatives.

Authors:  Szilvia Kanizsai; József Ongrádi; János Aradi; Károly Nagy
Journal:  Pathol Oncol Res       Date:  2016-02-09       Impact factor: 3.201

Review 2.  Nucleocapsid protein function in early infection processes.

Authors:  James A Thomas; Robert J Gorelick
Journal:  Virus Res       Date:  2008-02-14       Impact factor: 3.303

3.  Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon.

Authors:  L D Giavedoni; T Yilma
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

4.  Genetic analysis of the zinc finger in the Moloney murine leukemia virus nucleocapsid domain: replacement of zinc-coordinating residues with other zinc-coordinating residues yields noninfectious particles containing genomic RNA.

Authors:  R J Gorelick; D J Chabot; D E Ott; T D Gagliardi; A Rein; L E Henderson; L O Arthur
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

5.  Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication.

Authors:  A H Kaplan; M Manchester; T Smith; Y L Yang; R Swanstrom
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

Review 6.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

7.  Amino-terminal polypeptides of vimentin are responsible for the changes in nuclear architecture associated with human immunodeficiency virus type 1 protease activity in tissue culture cells.

Authors:  R L Shoeman; C Hüttermann; R Hartig; P Traub
Journal:  Mol Biol Cell       Date:  2001-01       Impact factor: 4.138

8.  Inactivation of murine leukemia virus by compounds that react with the zinc finger in the viral nucleocapsid protein.

Authors:  A Rein; D E Ott; J Mirro; L O Arthur; W Rice; L E Henderson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

9.  Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor.

Authors:  J He; N R Landau
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

10.  Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication.

Authors:  A Steinkasserer; R Harrison; A Billich; F Hammerschmid; G Werner; B Wolff; P Peichl; G Palfi; W Schnitzel; E Mlynar
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.